Fam-Trastuzumab Deruxtecan-nxki (Monograph)Brand name: Enhertu Drug class: Antineoplastic Agents Chemical name: Glycinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-l-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-...
Drug class: HER2 inhibitors En español Patient resources Fam-trastuzumab deruxtecan-nxki advanced reading Other brands Enhertu Professional resources Fam-Trastuzumab Deruxtecan-nxki monograph Other brands Enhertu Related treatment guides Breast Cancer Breast Cancer, Metastatic Gastric Cancer Non Small...
生物活性：Trastuzumab deruxtecan (DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-药物偶联物 (ADC)。曲妥珠单抗 deruxtecan 由人源化抗 HER2 抗体、酶促可裂解的肽接头和拓扑异构酶 I 抑制剂组成。 Trastuzumab deruxtecan可用于HER2阳性乳腺癌和胃癌的研究[1][2]。体外：Trastuzumab deruxtecan（1...
昨日,美国食品药品监督管理局(FDA)已同意优先审查trastuzumab deruxtecan的补充生物制剂许可申请(sBLA),用于治疗患有不可切除或转移性人类表皮生长因子受体2(her2)阳性(免疫组织化学【IHC】3+)实体瘤的成年人,这些人之前接受过治疗或没有令人满意的替代治疗方案。处方药使用费法案的目标日期定在2024年第二季度。 该药...
class of medications called kinase inhibitors. It inhibits a protein called Wee1. Inhibition of the Wee1 protein can make tumor cells more vulnerable to chemotherapy drugs, leading to tumor cell death. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is ...
生物活性:Trastuzumab deruxtecan (DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-药物偶联物 (ADC)。曲妥珠单抗 deruxtecan 由人源化抗 HER2 抗体、酶促可裂解的肽接头和拓扑异构酶 I 抑制剂组成。 Trastuzumab deruxtecan可用于HER2阳性乳腺癌和胃癌的研究[1][2]。
Trastuzumab Deruxtecan (a type of HER2-directed antibody drug conjugate) Tucatinib (Tyrosine Kinase HER2 Inhibitor) Ado-trastuzumab emtansine or T-DM1 (a type of HER2-targeted antibody-drug conjugate) 显示全部 开始日期2024-11-01 申办/合作机构 ...
Generic Name:fam-trastuzumab deruxtecan-nxki for injection Brand Name:Enhertu Drug Class:,Antineoplastic Topoisomerase Inhibitors,Antineoplastics, Anti-HER2 Medical Editor:John P. Cunha, DO, FACOEPLast updated on RxList:4/12/2024 homedrugs a-z listenhertu (fam-trastuzumab deruxtecan-nxki for ...
生物活性:Trastuzumab deruxtecan (DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-药物偶联物 (ADC)。曲妥珠单抗 deruxtecan 由人源化抗 HER2 抗体、酶促可裂解的肽接头和拓扑异构酶 I 抑制剂组成。 Trastuzumab deruxtecan可用于HER2阳性乳腺癌和胃癌的研究[1][2]。 体外:Trastuzumab deruxtecan(1 ...
fam-trastuzumab deruxtecan-nxki是HER2定向的抗体-药物偶联物。该抗体是人源化抗HER2 IgG1。小分子DXd是拓扑异构酶I抑制剂,通过可裂解的接头与抗体连接。与肿瘤细胞上的HER2结合后,fam-trastuzumab deruxtecan-nxki通过溶酶体酶进行内在化和细胞内接头裂解。释放后,可透膜的DXd引起DNA损伤和凋亡细胞死亡。